$26.8M
+$26.8M this year1 filing since 2026 · latest Equity filed
Promaxo builds a compact, single-sided, low-field MRI system designed to sit inside a urologist's office rather than a hospital imaging suite. The platform is FDA 510(k)-cleared for MRI-guided prostate biopsy and combines imaging, AI-assisted lesion identification, and robotic needle guidance in one machine. Operating at roughly 58-74 mT with a limited fringe field, it installs without the shielding and facility upgrades a conventional scanner requires. The company was founded in 2016 and is backed by a portfolio of over 200 patents.
What sets it apart
A single-sided, open-architecture, low-field MRI small enough to install in a physician's office, letting urologists image and perform MR-guided prostate biopsies at the point of care instead of referring patients out to a hospital scanner.
An office-based, single-sided, low-field open MRI platform cleared by the FDA under 510(k) for MRI-guided prostate biopsy, integrating imaging, AI-driven insights and robotic guidance into one compact machine.
